Whole-exome sequencing identification of the risk variants in a middle-aged adult with intracranial Ewing’s sarcoma: A case report

Figure 1 Immunohistochemical evaluation of the proband pathological sections. A: Hematoxylin and eosin staining; B: Vimentin (+) staining, C: CD99 (+) staining, D: CK (-) staining; E: CD56 (+) staining; F: Fluorescence in situ hybridization imaging. A: Magnification × 100; B-E: Magnification × 200; F: Magnification × 1000.

Figure 2 Brain magnetic resonance imaging scan. A: Preoperative brain magnetic resonance imaging (MRI) of the patient; B: Postoperative brain MRI; C: Brain MRI following radio and chemotherapy.

Figure 3 Biological analysis of risk variants. A and B: Neurofibromin 1 Leu 190 (A) and secreted protein acidic and rich in cysteine (SPARC) Arg 255 (B) across species; C and D: Schematic diagrams of the 3D SPARC protein structure prior to and after C > D mutation, which altered the amino acid at position 255 from an arginine to a histidine.

Figure 4 Timeline of the patient’s clinical course. PR: Partial response; SD: Stable disease.